 
 
GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                                                                Synonyms: Adcetris® | anti-CD30 ADC SGN-35 | SGN 35
                                 brentuximab vedotin is an approved drug (FDA (2011), EMA (2012)) Compound class: 
                                                            Antibody
                                 
                                    
                                        Comment: Antibody-drug conjugate (ADC) that combines an anti-CD30 antibody and the drug monomethyl auristatin E (MMAE). The PubChem ID for the MMAE component compound is CID 11542188. The invention of this ADC is claimed in patent US7090843 [4] and the original article describing the parent antibody (C10 or AC10) is [1]. Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. | 
| Classification  | |
| Compound class | Antibody | 
| Approved drug? | Yes. US FDA (2011) | EU EMA (2012) | 
| International Nonproprietary Names  | |
| INN number | INN | 
| 9144 | brentuximab vedotin | 
| Synonyms  | 
| Adcetris® | anti-CD30 ADC SGN-35 | SGN 35 | 
| Database Links  | |
| Specialist databases | |
| IMGT/mAb-DB | 324 | 
| Other databases | |
| GtoPdb PubChem SID | 178103378 | 
| PubChem SID | 178103378 | 
| Search PubMed clinical trials | brentuximab vedotin | 
| Search PubMed titles | brentuximab vedotin | 
| Search PubMed titles/abstracts | brentuximab vedotin | 
| Wikipedia | Brentuximab_vedotin |